[The problem of the interferon therapy of patients with chronic viral hepatitis].
In this work the results of the clinico-immunological evaluation of the therapeutic effectiveness of alpha-interferon preparations are presented and criteria suitable for use in screening patients with chronic virus hepatitis, sensitive to interferon therapy, are discussed. The study revealed that the use of alpha-interferon preparations in single doses of 1-3 x 10(6) in a prolonged course of treatment (6-12 months) facilitated essential improvement in the clinical course of the disease and ensures correction of the immune status in 55.6% of patients with chronic active hepatitis (CAH) resulting in cirrhosis of the liver and 57.9% of patients with CAH moderate activity. Indications for the use of alpha-interferon preparations in patients with CAH-induced cirrhosis were high activity of the cytolytic process, the presence of immunodeficiency, faintly pronounced autoimmune process and the presence of protein shifts.
L N
LN
Kokoreva
A V
AV
Zmyzgova
N B
NB
Shalygina
D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000628:therapy*; D003699:Hepatitis D / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007370:Interferon Type I / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000097:blood / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins
Problema interferonoterapii bol'nykh khronicheskim virusnym gepatitom.